Speaker(s): 

Varun Pulakanti, MD, Staff Member, Geisinger - has nothing to disclose.

Learning Objectives

At the conclusion of this session, the participant should be able to: 

• Explain the potential role of Tirofiban as adjunctive agent for acute stroke management
• Discuss out current Tirofiban protocol at our institution and discuss escalation

After viewing this session, the participants should be able to answer the following questions:

• Is there a role/indication for expanding Tirofiban at our institution?
• How would this compare to other adjunctive strategies like Cangrelor or Asudexian?
• What does this tell us about the benefit of IV thrombolytics for treatment of small vessel ischemia?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anthony Noto, MD, David Ermak, DO, Lisa Wasko, BSN, RN, SCRN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None 

Follow up Questions: 

• What is our standard neuroimaging for TGA?
• How often are we considering diagnosis but actually confirming it?
• What to do when we find Jugular stenosis in these patients?